ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : -3 مورد

Treatment of refractory psoriatic juvenile idiopathic arthritis

Treatment of refractory psoriatic juvenile idiopathic arthritis
To be used with UpToDate content on treatment of psJIA.

bDMARD: biologic disease-modifying antirheumatic drug; csDMARD: conventional synthetic disease-modifying antirheumatic drug; IA: intraarticular; IL: interleukin; NSAID: nonsteroidal antiinflammatory drug; psJIA: psoriatic juvenile idiopathic arthritis; TNF: tumor necrosis factor.

* Patients are considered to have refractory disease if they do not respond to NSAIDs or IA glucocorticoids within 4 to 6 weeks or to csDMARDs within 8 weeks.

¶ For drug dosing, adverse effects, and monitoring, refer to UpToDate content on the treatment of psJIA.
Graphic 145198 Version 1.0